Cary Street Partners Financial LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Cary Street Partners Financial LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 99,154 shares of the biopharmaceutical company's stock, valued at approximately $4,741,000. Cary Street Partners Financial LLC owned approximately 0.08% of Halozyme Therapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC increased its holdings in Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Halozyme Therapeutics by 0.6% in the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock valued at $1,688,000 after purchasing an additional 200 shares in the last quarter. Baird Financial Group Inc. raised its holdings in Halozyme Therapeutics by 2.0% in the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock worth $532,000 after purchasing an additional 221 shares during the period. CreativeOne Wealth LLC boosted its position in Halozyme Therapeutics by 1.6% during the fourth quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after purchasing an additional 294 shares in the last quarter. Finally, State of New Jersey Common Pension Fund D grew its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock valued at $2,279,000 after purchasing an additional 302 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on HALO. Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. JPMorgan Chase & Co. increased their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, HC Wainwright reiterated a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Friday, April 25th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $63.78.

Halozyme Therapeutics Price Performance

Shares of HALO traded down $1.87 on Friday, reaching $65.86. The stock had a trading volume of 2,501,725 shares, compared to its average volume of 1,499,455. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm has a market capitalization of $8.14 billion, a PE ratio of 19.20, a PEG ratio of 0.42 and a beta of 1.26. The firm has a 50-day moving average of $61.45 and a 200 day moving average of $55.83. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The company had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. During the same period in the prior year, the firm earned $0.79 EPS. The firm's quarterly revenue was up 35.2% on a year-over-year basis. Sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jeffrey William Henderson sold 503 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the transaction, the director now owns 33,108 shares in the company, valued at $2,120,567.40. This represents a 1.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,697 shares of company stock valued at $1,276,552 over the last 90 days. Corporate insiders own 2.90% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.